Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

3.22
+0.06001.90%
Pre-market: 3.18-0.0400-1.24%04:01 EDT
Volume:1.54M
Turnover:4.92M
Market Cap:307.83M
PE:-2.68
High:3.26
Open:3.15
Low:3.04
Close:3.16
52wk High:8.59
52wk Low:2.74
Shares:95.60M
Float Shares:79.40M
Volume Ratio:1.09
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2031
EPS(LYR):-3.9514
ROE:-32.54%
ROA:-8.59%
PB:1.01
PE(LYR):-0.81

Loading ...

Myriad Genetics, Inc. : Piper Sandler Cuts to Underweight from Overweight; Cuts Target Price to $2 from $5.45

THOMSON REUTERS
·
35 mins ago

Myriad Genetics to Present at Wells Fargo Healthcare Conference

Reuters
·
Aug 27

Myriad Genetics, Inc. : Jefferies Cuts Target Price to $2.5 from $4

THOMSON REUTERS
·
Aug 21

Myriad Genetics is Maintained at Equal-Weight by Stephens & Co.

Dow Jones
·
Aug 18

Myriad Genetics is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Aug 03

Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (ATR), Myriad Genetics (MYGN) and HCA Healthcare (HCA)

TIPRANKS
·
Aug 03

Analysts Conflicted on These Healthcare Names: Myriad Genetics (MYGN) and Biodesix (BDSX)

TIPRANKS
·
Aug 01

Myriad Genetics is Maintained at Hold by TD Cowen

Dow Jones
·
Aug 01

Myriad Genetics Down over 45%, on Pace for Record Percent Decrease

Dow Jones
·
Aug 01

Myriad Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Myriad Genetics: Q2 Miss, Guidance Cut Lead to Lower $4 Price Target and Maintained Hold Rating

TIPRANKS
·
Jul 31

Myriad Genetics Lowers FY26 Rev Outlook

Dow Jones
·
Jul 31

Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M

TIPRANKS
·
Jul 31

Myriad Genetics reports Q2 EPS (25c), consensus (6c)

TIPRANKS
·
Jul 31

Myriad Genetics Q2 FY26 Operating Loss Narrows to $38.9 Million; Revenue Drops 11% to $190.7 Million

Reuters
·
Jul 31

Myriad Genetics Q2 Adj. EPS $(0.25) Misses $(0.06) Estimate, Sales $190.700M Miss $206.029M Estimate

Benzinga Earnings
·
Jul 31

Myriad Genetics Q2 Revenue USD 190.7 Million Vs. IBES Estimate USD 206 Million

Reuters
·
Jul 31

Myriad Genetics - Suspends Full-Year 2026 Adj Ebitda Guidance

THOMSON REUTERS
·
Jul 31

Myriad Genetics Outlook FY Revenue USD 770-790 Million

THOMSON REUTERS
·
Jul 31

Myriad Genetics Q2 Gross Margin 66.6%

THOMSON REUTERS
·
Jul 31